factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 1226-1232 | 1226-1232 | T67 | blocks | INHIBITS | 1,226 | 1,232 | preserve | 1197-1220 | 1213-1220 | T57 | receptor fusion protein | AminoAcidPeptideOrProtein | 1,197 | 1,220 | preserve | 1233-1254 | 1248-1254 | T58 | tumor necrosis factor | AminoAcidPeptideOrProtein | 1,233 | 1,254 | A5 | Etanercept, a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for treatment of patients with refractory rheumatoid arthritis. | 1155-1391 | 1,155 | 1,391 | Etanercept, a bioengineered soluble @SUBJECT$ that @PREDICAT$ @OBJECT$ activity, is the first compound in this class to be approved for treatment of patients with refractory rheumatoid arthritis. |
Fact | preserve | 774-783 | 774-783 | T42 | Treatment | TREATS | 774 | 783 | preserve | 833-870 | 865-870 | T36 | disease-modifying antirheumatic drugs | PharmacologicSubstance | 833 | 870 | preserve | 787-807 | 798-807 | T35 | rheumatoid arthritis | DiseaseOrSyndrome | 787 | 807 | A6 | Treatment of rheumatoid arthritis typically involves disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and low-dose corticosteroids--often used in combination. | 774-973 | 774 | 973 | @PREDICAT$ of @OBJECT$ typically involves @SUBJECT$ , nonsteroidal anti-inflammatory drugs, and low-dose corticosteroids--often used in combination. |
Probable | preserve | 153-158 | 153-158 | T9 | cause | CAUSES | 153 | 158 | preserve | 115-143 | 136-143 | T6 | chronic inflammatory disease | DiseaseOrSyndrome | 115 | 143 | preserve | 181-191 | 181-191 | T8 | disability | PathologicFunction | 181 | 191 | A7 | Rheumatoid arthritis is a chronic inflammatory disease that can cause severe pain and disability. | 89-192 | 89 | 192 | Rheumatoid arthritis is a @SUBJECT$ that can @PREDICAT$ severe pain and @OBJECT$ . |
Fact | preserve | 1547-1551 | 1547-1551 | T83 | with | PROCESS_OF | 1,547 | 1,551 | preserve | 1552-1572 | 1563-1572 | T79 | rheumatoid arthritis | DiseaseOrSyndrome | 1,552 | 1,572 | preserve | 1539-1546 | 1539-1546 | T78 | persons | PopulationGroup | 1,539 | 1,546 | A8 | Therapeutic trials indicate that etanercept can reduce disease activity with relatively few drug-related adverse effects, thus helping persons with rheumatoid arthritis return to more normal, healthy lives. | 1392-1616 | 1,392 | 1,616 | Therapeutic trials indicate that etanercept can reduce disease activity with relatively few drug-related adverse effects, thus helping @OBJECT$ @PREDICAT$ @SUBJECT$ return to more normal, healthy lives. |
Probable | preserve | 153-158 | 153-158 | T9 | cause | CAUSES | 153 | 158 | preserve | 115-143 | 136-143 | T6 | chronic inflammatory disease | DiseaseOrSyndrome | 115 | 143 | preserve | 159-170 | 166-170 | T7 | severe pain | SignOrSymptom | 159 | 170 | A9 | Rheumatoid arthritis is a chronic inflammatory disease that can cause severe pain and disability. | 89-192 | 89 | 192 | Rheumatoid arthritis is a @SUBJECT$ that can @PREDICAT$ @OBJECT$ and disability. |
Fact | preserve | 386-390 | 386-390 | T21 | with | PROCESS_OF | 386 | 390 | preserve | 391-411 | 402-411 | T18 | rheumatoid arthritis | DiseaseOrSyndrome | 391 | 411 | preserve | 377-385 | 377-385 | T17 | patients | PatientOrDisabledGroup | 377 | 385 | A10 | However, the demonstration of early joint damage in patients with rheumatoid arthritis has emphasized the importance of early identification and treatment. | 319-486 | 319 | 486 | However, the demonstration of early joint damage in @OBJECT$ @PREDICAT$ @SUBJECT$ has emphasized the importance of early identification and treatment. |
Fact | preserve | 1326-1335 | 1326-1335 | T68 | treatment | TREATS | 1,326 | 1,335 | preserve | 1155-1165 | 1155-1165 | T54 | Etanercept | AminoAcidPeptideOrProtein | 1,155 | 1,165 | preserve | 1370-1390 | 1381-1390 | T66 | rheumatoid arthritis | DiseaseOrSyndrome | 1,370 | 1,390 | A11 | Etanercept, a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for treatment of patients with refractory rheumatoid arthritis. | 1155-1391 | 1,155 | 1,391 | @SUBJECT$ , a bioengineered soluble receptor fusion protein that blocks tumor necrosis factor activity, is the first compound in this class to be approved for @PREDICAT$ of patients with refractory @OBJECT$ . |
Fact | preserve | 774-783 | 774-783 | T42 | Treatment | TREATS | 774 | 783 | preserve | 930-945 | 930-945 | T39 | corticosteroids | Hormone | 930 | 945 | preserve | 787-807 | 798-807 | T35 | rheumatoid arthritis | DiseaseOrSyndrome | 787 | 807 | A12 | Treatment of rheumatoid arthritis typically involves disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and low-dose corticosteroids--often used in combination. | 774-973 | 774 | 973 | @PREDICAT$ of @OBJECT$ typically involves disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and low-dose @SUBJECT$ --often used in combination. |
Fact | preserve | 782-791 | 782-791 | T66 | treatment | TREATS | 782 | 791 | preserve | 825-829 | 825-829 | T58 | DSCG | OrganicChemical | 825 | 829 | preserve | 795-804 | 795-804 | T56 | asthmatic | DiseaseOrSyndrome | 795 | 804 | A1 | The treatment of asthmatic patients with DSCG downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. | 778-962 | 778 | 962 | The @PREDICAT$ of @OBJECT$ patients with @SUBJECT$ downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. |
Fact | preserve | 830-843 | 830-843 | T68 | downregulated | DISRUPTS | 830 | 843 | preserve | 825-829 | 825-829 | T58 | DSCG | OrganicChemical | 825 | 829 | preserve | 857-865 | 857-865 | T60 | adhesion | AcquiredAbnormality | 857 | 865 | A2 | The treatment of asthmatic patients with DSCG downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. | 778-962 | 778 | 962 | The treatment of asthmatic patients with @SUBJECT$ @PREDICAT$ the monocyte @OBJECT$ to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. |
Fact | preserve | 186-188 | 186-188 | T31 | of | LOCATION_OF | 186 | 188 | preserve | 189-223 | 218-223 | T19 | peripheral blood mononuclear cells | Cell | 189 | 223 | preserve | 177-185 | 177-185 | T18 | adhesion | AcquiredAbnormality | 177 | 185 | A3 | In this study we have compared the adhesion of peripheral blood mononuclear cells (PBMC) to human umbilical vein endothelial cells (HUVEC) in a healthy control group with two groups of allergic asthmatics, not treated or treated with disodium cromoglycate (DSCG). | 142-423 | 142 | 423 | In this study we have compared the @OBJECT$ @PREDICAT$ @SUBJECT$ (PBMC) to human umbilical vein endothelial cells (HUVEC) in a healthy control group with two groups of allergic asthmatics, not treated or treated with disodium cromoglycate (DSCG). |
Fact | preserve | 375-382 | 375-382 | T32 | treated | TREATS | 375 | 382 | preserve | 394-415 | 403-415 | T30 | disodium cromoglycate | OrganicChemical | 394 | 415 | preserve | 348-358 | 348-358 | T28 | asthmatics | DiseaseOrSyndrome | 348 | 358 | A4 | In this study we have compared the adhesion of peripheral blood mononuclear cells (PBMC) to human umbilical vein endothelial cells (HUVEC) in a healthy control group with two groups of allergic asthmatics, not treated or treated with disodium cromoglycate (DSCG). | 142-423 | 142 | 423 | In this study we have compared the adhesion of peripheral blood mononuclear cells (PBMC) to human umbilical vein endothelial cells (HUVEC) in a healthy control group with two groups of allergic @OBJECT$ , not treated or @PREDICAT$ with @SUBJECT$ (DSCG). |
Fact | preserve | 1029-1046 | 1038-1046 | T80 | monocyte adhesion | LOCATION_OF | 1,029 | 1,046 | preserve | 1029-1037 | 1029-1037 | T74 | monocyte | Cell | 1,029 | 1,037 | preserve | 1038-1046 | 1038-1046 | T75 | adhesion | AcquiredAbnormality | 1,038 | 1,046 | A5 | The DSCG may have a therapeutic effect on the regulation of monocyte adhesion in inflammatory and allergic diseases. | 963-1092 | 963 | 1,092 | The DSCG may have a therapeutic effect on the regulation of @SUBJECT$ @PREDICAT$ @OBJECT$ in inflammatory and allergic diseases. |
Fact | preserve | 782-791 | 782-791 | T66 | treatment | TREATS | 782 | 791 | preserve | 825-829 | 825-829 | T58 | DSCG | OrganicChemical | 825 | 829 | preserve | 811-819 | 811-819 | T57 | patients | PatientOrDisabledGroup | 811 | 819 | A6 | The treatment of asthmatic patients with DSCG downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. | 778-962 | 778 | 962 | The @PREDICAT$ of asthmatic @OBJECT$ with @SUBJECT$ downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. |
Fact | preserve | 45-93 | 85-93 | T13 | peripheral blood mononuclear cell adhesion | LOCATION_OF | 45 | 93 | preserve | 45-78 | 74-78 | T4 | peripheral blood mononuclear cell | Cell | 45 | 78 | preserve | 85-93 | 85-93 | T5 | adhesion | AcquiredAbnormality | 85 | 93 | A7 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. | 0-141 | 0 | 141 | Effect of disodium cromoglycate treatment on @SUBJECT$ @PREDICAT$ @OBJECT$ to cultured endothelium in allergic asthmatics. |
Fact | preserve | 10-41 | 32-41 | T15 | disodium cromoglycate treatment | AFFECTS | 10 | 41 | preserve | 10-31 | 19-31 | T2 | disodium cromoglycate | OrganicChemical | 10 | 31 | preserve | 85-93 | 85-93 | T5 | adhesion | AcquiredAbnormality | 85 | 93 | A10 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. | 0-141 | 0 | 141 | Effect of @SUBJECT$ @PREDICAT$ on peripheral blood mononuclear cell @OBJECT$ to cultured endothelium in allergic asthmatics. |
Fact | preserve | 0-6 | 0-6 | T11 | Effect | AFFECTS | 0 | 6 | preserve | 32-41 | 32-41 | T3 | treatment | TherapeuticOrPreventiveProcedure | 32 | 41 | preserve | 85-93 | 85-93 | T5 | adhesion | AcquiredAbnormality | 85 | 93 | A11 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. | 0-141 | 0 | 141 | @PREDICAT$ of disodium cromoglycate @SUBJECT$ on peripheral blood mononuclear cell @OBJECT$ to cultured endothelium in allergic asthmatics. |
Fact | preserve | 795-819 | 811-819 | T67 | asthmatic patients | PROCESS_OF | 795 | 819 | preserve | 795-804 | 795-804 | T56 | asthmatic | DiseaseOrSyndrome | 795 | 804 | preserve | 811-819 | 811-819 | T57 | patients | PatientOrDisabledGroup | 811 | 819 | A13 | The treatment of asthmatic patients with DSCG downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. | 778-962 | 778 | 962 | The treatment of @SUBJECT$ @PREDICAT$ @OBJECT$ with DSCG downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. |
Fact | preserve | 848-865 | 857-865 | T69 | monocyte adhesion | LOCATION_OF | 848 | 865 | preserve | 848-856 | 848-856 | T59 | monocyte | Cell | 848 | 856 | preserve | 857-865 | 857-865 | T60 | adhesion | AcquiredAbnormality | 857 | 865 | A14 | The treatment of asthmatic patients with DSCG downregulated the monocyte adhesion to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. | 778-962 | 778 | 962 | The treatment of asthmatic patients with DSCG downregulated the @SUBJECT$ @PREDICAT$ @OBJECT$ to cultured endothelial cells (ECs) and this was comparable to the group of normal donors. |
Fact | preserve | 10-41 | 32-41 | T10 | disodium cromoglycate treatment | ISA | 10 | 41 | preserve | 10-31 | 19-31 | T2 | disodium cromoglycate | OrganicChemical | 10 | 31 | preserve | 32-41 | 32-41 | T3 | treatment | TherapeuticOrPreventiveProcedure | 32 | 41 | A15 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. | 0-141 | 0 | 141 | Effect of @SUBJECT$ @PREDICAT$ @OBJECT$ on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. |
Fact | preserve | 10-41 | 32-41 | T12 | disodium cromoglycate treatment | USES | 10 | 41 | preserve | 32-41 | 32-41 | T3 | treatment | TherapeuticOrPreventiveProcedure | 32 | 41 | preserve | 10-31 | 19-31 | T2 | disodium cromoglycate | OrganicChemical | 10 | 31 | A16 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. | 0-141 | 0 | 141 | Effect of @OBJECT$ @PREDICAT$ @SUBJECT$ on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. |
Fact | preserve | 559-561 | 559-561 | T43 | of | LOCATION_OF | 559 | 561 | preserve | 562-573 | 562-573 | T41 | lymphocytes | Cell | 562 | 573 | preserve | 544-552 | 544-552 | T40 | adhesion | AcquiredAbnormality | 544 | 552 | A17 | No differences in the adhesion of lymphocytes were observed in any of the groups. | 522-609 | 522 | 609 | No differences in the @OBJECT$ @PREDICAT$ @SUBJECT$ were observed in any of the groups. |
Fact | preserve | 118-120 | 118-120 | T14 | in | COEXISTS_WITH | 118 | 120 | preserve | 85-93 | 85-93 | T5 | adhesion | AcquiredAbnormality | 85 | 93 | preserve | 130-140 | 130-140 | T9 | asthmatics | DiseaseOrSyndrome | 130 | 140 | A18 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. | 0-141 | 0 | 141 | Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell @SUBJECT$ to cultured endothelium @PREDICAT$ allergic @OBJECT$ . |
Fact | preserve | 1015-1025 | 1015-1025 | T79 | regulation | AFFECTS | 1,015 | 1,025 | preserve | 967-971 | 967-971 | T71 | DSCG | OrganicChemical | 967 | 971 | preserve | 1038-1046 | 1038-1046 | T75 | adhesion | AcquiredAbnormality | 1,038 | 1,046 | A20 | The DSCG may have a therapeutic effect on the regulation of monocyte adhesion in inflammatory and allergic diseases. | 963-1092 | 963 | 1,092 | The @SUBJECT$ may have a therapeutic effect on the @PREDICAT$ of monocyte @OBJECT$ in inflammatory and allergic diseases. |
Fact | preserve | 939-955 | 948-955 | T73 | levodopa therapy | ISA | 939 | 955 | preserve | 939-947 | 939-947 | T70 | levodopa | AminoAcidPeptideOrProtein | 939 | 947 | preserve | 948-955 | 948-955 | T71 | therapy | TherapeuticOrPreventiveProcedure | 948 | 955 | A1 | Goals of therapy in patients less than 60 years of age include sparing levodopa therapy and providing neuroprotection. | 862-992 | 862 | 992 | Goals of therapy in patients less than 60 years of age include sparing @SUBJECT$ @PREDICAT$ @OBJECT$ and providing neuroprotection. |
Fact | preserve | 793-815 | 808-815 | T63 | levodopa therapy | USES | 793 | 815 | preserve | 808-815 | 808-815 | T59 | therapy | TherapeuticOrPreventiveProcedure | 808 | 815 | preserve | 793-801 | 793-801 | T58 | levodopa | AminoAcidPeptideOrProtein | 793 | 801 | A2 | COMT inhibitors may be useful adjuncts to levodopa therapy but are plagued with serious adverse effects. | 751-861 | 751 | 861 | COMT inhibitors may be useful adjuncts to @OBJECT$ @PREDICAT$ @SUBJECT$ but are plagued with serious adverse effects. |
Fact | preserve | 564-575 | 564-575 | T48 | stimulation | STIMULATES | 564 | 575 | preserve | 501-518 | 510-518 | T39 | Dopamine agonists | PharmacologicSubstance | 501 | 518 | preserve | 579-597 | 588-597 | T44 | dopamine receptors | AminoAcidPeptideOrProtein | 579 | 597 | A3 | Dopamine agonists hold promise because of more sustained stimulation of dopamine receptors and possibly an antioxidant effect. | 501-633 | 501 | 633 | @SUBJECT$ hold promise because of more sustained @PREDICAT$ of @OBJECT$ and possibly an antioxidant effect. |
Fact | preserve | 939-955 | 948-955 | T75 | levodopa therapy | USES | 939 | 955 | preserve | 948-955 | 948-955 | T71 | therapy | TherapeuticOrPreventiveProcedure | 948 | 955 | preserve | 939-947 | 939-947 | T70 | levodopa | AminoAcidPeptideOrProtein | 939 | 947 | A4 | Goals of therapy in patients less than 60 years of age include sparing levodopa therapy and providing neuroprotection. | 862-992 | 862 | 992 | Goals of therapy in patients less than 60 years of age include sparing @OBJECT$ @PREDICAT$ @SUBJECT$ and providing neuroprotection. |
Fact | preserve | 735-737 | 735-737 | T53 | in | TREATS | 735 | 737 | preserve | 662-678 | 662-678 | T51 | anticholinergics | PharmacologicSubstance | 662 | 678 | preserve | 742-749 | 742-749 | T52 | elderly | AgeGroup | 742 | 749 | A5 | Selegiline, amantadine, and anticholinergics are still used but must be employed with caution in the elderly. | 634-750 | 634 | 750 | Selegiline, amantadine, and @SUBJECT$ are still used but must be employed with caution @PREDICAT$ the @OBJECT$ . |
Fact | preserve | 354-395 | 391-395 | T35 | Levodopa is the most effective drug | ISA | 354 | 395 | preserve | 354-362 | 354-362 | T25 | Levodopa | AminoAcidPeptideOrProtein | 354 | 362 | preserve | 391-395 | 391-395 | T28 | drug | PharmacologicSubstance | 391 | 395 | A6 | Levodopa is the most effective drug for Parkinson's disease, but its long-term use is associated with significant motor complications. | 354-500 | 354 | 500 | @SUBJECT$ @PREDICAT$ @OBJECT$ for Parkinson's disease, but its long-term use is associated with significant motor complications. |
Fact | preserve | 735-737 | 735-737 | T53 | in | TREATS | 735 | 737 | preserve | 634-644 | 634-644 | T49 | Selegiline | OrganicChemical | 634 | 644 | preserve | 742-749 | 742-749 | T52 | elderly | AgeGroup | 742 | 749 | A7 | Selegiline, amantadine, and anticholinergics are still used but must be employed with caution in the elderly. | 634-750 | 634 | 750 | @SUBJECT$ , amantadine, and anticholinergics are still used but must be employed with caution @PREDICAT$ the @OBJECT$ . |
Fact | preserve | 354-395 | 391-395 | T38 | Levodopa is the most effective drug | TREATS | 354 | 395 | preserve | 354-362 | 354-362 | T25 | Levodopa | AminoAcidPeptideOrProtein | 354 | 362 | preserve | 400-419 | 412-419 | T29 | Parkinson's disease | DiseaseOrSyndrome | 400 | 419 | A9 | Levodopa is the most effective drug for Parkinson's disease, but its long-term use is associated with significant motor complications. | 354-500 | 354 | 500 | @SUBJECT$ @PREDICAT$ for @OBJECT$ , but its long-term use is associated with significant motor complications. |
Fact | preserve | 446-456 | 446-456 | T37 | associated | ASSOCIATED_WITH | 446 | 456 | preserve | 354-362 | 354-362 | T25 | Levodopa | AminoAcidPeptideOrProtein | 354 | 362 | preserve | 486-499 | 486-499 | T34 | complications | PathologicFunction | 486 | 499 | A10 | Levodopa is the most effective drug for Parkinson's disease, but its long-term use is associated with significant motor complications. | 354-500 | 354 | 500 | @SUBJECT$ is the most effective drug for Parkinson's disease, but its long-term use is @PREDICAT$ with significant motor @OBJECT$ . |
Fact | preserve | 793-815 | 808-815 | T62 | levodopa therapy | ISA | 793 | 815 | preserve | 793-801 | 793-801 | T58 | levodopa | AminoAcidPeptideOrProtein | 793 | 801 | preserve | 808-815 | 808-815 | T59 | therapy | TherapeuticOrPreventiveProcedure | 808 | 815 | A12 | COMT inhibitors may be useful adjuncts to levodopa therapy but are plagued with serious adverse effects. | 751-861 | 751 | 861 | COMT inhibitors may be useful adjuncts to @SUBJECT$ @PREDICAT$ @OBJECT$ but are plagued with serious adverse effects. |
Fact | preserve | 153-169 | 162-169 | T16 | surgical therapy | ISA | 153 | 169 | preserve | 153-161 | 153-161 | T11 | surgical | TherapeuticOrPreventiveProcedure | 153 | 161 | preserve | 162-169 | 162-169 | T12 | therapy | TherapeuticOrPreventiveProcedure | 162 | 169 | A13 | Despite new medical and surgical therapy, mortality rates for Parkinson's disease remain unchanged. | 129-234 | 129 | 234 | Despite new medical and @SUBJECT$ @PREDICAT$ @OBJECT$ , mortality rates for Parkinson's disease remain unchanged. |
Fact | preserve | 153-169 | 162-169 | T18 | surgical therapy | TREATS | 153 | 169 | preserve | 153-161 | 153-161 | T11 | surgical | TherapeuticOrPreventiveProcedure | 153 | 161 | preserve | 191-210 | 203-210 | T14 | Parkinson's disease | DiseaseOrSyndrome | 191 | 210 | A15 | Despite new medical and surgical therapy, mortality rates for Parkinson's disease remain unchanged. | 129-234 | 129 | 234 | Despite new medical and @SUBJECT$ @PREDICAT$ , mortality rates for @OBJECT$ remain unchanged. |
Fact | preserve | 735-737 | 735-737 | T53 | in | TREATS | 735 | 737 | preserve | 646-656 | 646-656 | T50 | amantadine | OrganicChemical | 646 | 656 | preserve | 742-749 | 742-749 | T52 | elderly | AgeGroup | 742 | 749 | A16 | Selegiline, amantadine, and anticholinergics are still used but must be employed with caution in the elderly. | 634-750 | 634 | 750 | Selegiline, @SUBJECT$ , and anticholinergics are still used but must be employed with caution @PREDICAT$ the @OBJECT$ . |
Fact | preserve | 396-399 | 396-399 | T36 | for | TREATS | 396 | 399 | preserve | 391-395 | 391-395 | T28 | drug | PharmacologicSubstance | 391 | 395 | preserve | 400-419 | 412-419 | T29 | Parkinson's disease | DiseaseOrSyndrome | 400 | 419 | A17 | Levodopa is the most effective drug for Parkinson's disease, but its long-term use is associated with significant motor complications. | 354-500 | 354 | 500 | Levodopa is the most effective @SUBJECT$ @PREDICAT$ @OBJECT$ , but its long-term use is associated with significant motor complications. |
Fact | preserve | 879-881 | 879-881 | T74 | in | TREATS | 879 | 881 | preserve | 871-878 | 871-878 | T66 | therapy | TherapeuticOrPreventiveProcedure | 871 | 878 | preserve | 888-896 | 888-896 | T67 | patients | PatientOrDisabledGroup | 888 | 896 | A18 | Goals of therapy in patients less than 60 years of age include sparing levodopa therapy and providing neuroprotection. | 862-992 | 862 | 992 | Goals of @SUBJECT$ @PREDICAT$ @OBJECT$ less than 60 years of age include sparing levodopa therapy and providing neuroprotection. |
Fact | preserve | 2165-2173 | 2165-2173 | T136 | suffered | PROCESS_OF | 2,165 | 2,173 | preserve | 2174-2188 | 2182-2188 | T128 | cardiac events | DiseaseOrSyndrome | 2,174 | 2,188 | preserve | 2119-2127 | 2119-2127 | T124 | patients | PatientOrDisabledGroup | 2,119 | 2,127 | A1 | Four of the 36 patients with a negative symptom limited test suffered cardiac events within a year (two patients had a myocardial infarction and two had bypass surgery). | 2097-2279 | 2,097 | 2,279 | Four of the 36 @OBJECT$ with a negative symptom limited test @PREDICAT$ @SUBJECT$ within a year (two patients had a myocardial infarction and two had bypass surgery). |
Fact | preserve | 1873-1876 | 1873-1876 | T122 | had | PROCESS_OF | 1,873 | 1,876 | preserve | 1879-1892 | 1887-1892 | T107 | cardiac event | DiseaseOrSyndrome | 1,879 | 1,892 | preserve | 1827-1835 | 1827-1835 | T105 | patients | PatientOrDisabledGroup | 1,827 | 1,835 | A2 | Twenty three of the 75 patients who performed an exercise test had a cardiac event within one year (death, myocardial infarction, bypass surgery or PTCA); of these, 19 had a positive symptom limited exercise test and nine had a positive low level exercise test (p = 0.025). | 1804-2096 | 1,804 | 2,096 | Twenty three of the 75 @OBJECT$ who performed an exercise test @PREDICAT$ a @SUBJECT$ within one year (death, myocardial infarction, bypass surgery or PTCA); of these, 19 had a positive symptom limited exercise test and nine had a positive low level exercise test (p = 0.025). |
Fact | preserve | 1453-1455 | 1453-1455 | T83 | in | PROCESS_OF | 1,453 | 1,455 | preserve | 1426-1438 | 1431-1438 | T75 | test results | Finding | 1,426 | 1,438 | preserve | 1459-1467 | 1459-1467 | T77 | patients | PatientOrDisabledGroup | 1,459 | 1,467 | A3 | The test results were positive in 15 patients at the low level end point and in 39 patients (p < 0.001) at the symptom limited end point. | 1416-1565 | 1,416 | 1,565 | The @SUBJECT$ were positive @PREDICAT$ 15 @OBJECT$ at the low level end point and in 39 patients (p < 0.001) at the symptom limited end point. |
Fact | preserve | 1453-1455 | 1453-1455 | T83 | in | PROCESS_OF | 1,453 | 1,455 | preserve | 1426-1438 | 1431-1438 | T75 | test results | Finding | 1,426 | 1,438 | preserve | 1511-1519 | 1511-1519 | T80 | patients | PatientOrDisabledGroup | 1,511 | 1,519 | A4 | The test results were positive in 15 patients at the low level end point and in 39 patients (p < 0.001) at the symptom limited end point. | 1416-1565 | 1,416 | 1,565 | The @SUBJECT$ were positive @PREDICAT$ 15 patients at the low level end point and in 39 @OBJECT$ (p < 0.001) at the symptom limited end point. |
Fact | preserve | 1752-1755 | 1752-1755 | T103 | had | PROCESS_OF | 1,752 | 1,755 | preserve | 1773-1780 | 1773-1780 | T101 | symptom | SignOrSymptom | 1,773 | 1,780 | preserve | 1695-1703 | 1695-1703 | T95 | patients | PatientOrDisabledGroup | 1,695 | 1,703 | A6 | Two of these six patients had a positive low level exercise test and four had a positive symptom limited exercise test. | 1672-1803 | 1,672 | 1,803 | Two of these six @OBJECT$ had a positive low level exercise test and four @PREDICAT$ a positive @SUBJECT$ limited exercise test. |
Fact | preserve | 948-955 | 948-955 | T50 | perform | ADMINISTERED_TO | 948 | 955 | preserve | 971-984 | 980-984 | T49 | exercise test | DiagnosticProcedure | 971 | 984 | preserve | 926-934 | 926-934 | T47 | patients | PatientOrDisabledGroup | 926 | 934 | A7 | RESULTS: 75 of the 98 patients were able to perform a predischarge exercise test. | 898-985 | 898 | 985 | RESULTS: 75 of the 98 @OBJECT$ were able to @PREDICAT$ a predischarge @SUBJECT$ . |
Fact | preserve | 2418-2422 | 2418-2422 | T149 | with | PROCESS_OF | 2,418 | 2,422 | preserve | 2440-2459 | 2449-2459 | T144 | ST depression | Finding | 2,440 | 2,459 | preserve | 2409-2417 | 2409-2417 | T142 | patients | PatientOrDisabledGroup | 2,409 | 2,417 | A8 | CONCLUSION: Symptom limited exercise testing soon after thrombolytically treated myocardial infarction will identify more patients with exercise induced ST depression or chest pain than a low level test, and seems safe. | 2280-2512 | 2,280 | 2,512 | CONCLUSION: Symptom limited exercise testing soon after thrombolytically treated myocardial infarction will identify more @OBJECT$ @PREDICAT$ exercise induced @SUBJECT$ or chest pain than a low level test, and seems safe. |
Fact | preserve | 110-114 | 110-114 | T10 | with | PROCESS_OF | 110 | 114 | preserve | 115-136 | 126-136 | T7 | myocardial infarction | DiseaseOrSyndrome | 115 | 136 | preserve | 101-109 | 101-109 | T6 | patients | PatientOrDisabledGroup | 101 | 109 | A11 | Prognostic value of symptom limited versus low level exercise stress test before discharge in patients with myocardial infarction treated with thrombolytics. | 0-164 | 0 | 164 | Prognostic value of symptom limited versus low level exercise stress test before discharge in @OBJECT$ @PREDICAT$ @SUBJECT$ treated with thrombolytics. |
Fact | preserve | 1840-1849 | 1840-1849 | T121 | performed | ADMINISTERED_TO | 1,840 | 1,849 | preserve | 1859-1872 | 1868-1872 | T106 | exercise test | DiagnosticProcedure | 1,859 | 1,872 | preserve | 1827-1835 | 1827-1835 | T105 | patients | PatientOrDisabledGroup | 1,827 | 1,835 | A12 | Twenty three of the 75 patients who performed an exercise test had a cardiac event within one year (death, myocardial infarction, bypass surgery or PTCA); of these, 19 had a positive symptom limited exercise test and nine had a positive low level exercise test (p = 0.025). | 1804-2096 | 1,804 | 2,096 | Twenty three of the 75 @OBJECT$ who @PREDICAT$ an @SUBJECT$ had a cardiac event within one year (death, myocardial infarction, bypass surgery or PTCA); of these, 19 had a positive symptom limited exercise test and nine had a positive low level exercise test (p = 0.025). |
Fact | preserve | 98-100 | 98-100 | T9 | in | PROCESS_OF | 98 | 100 | preserve | 20-27 | 20-27 | T2 | symptom | SignOrSymptom | 20 | 27 | preserve | 101-109 | 101-109 | T6 | patients | PatientOrDisabledGroup | 101 | 109 | A13 | Prognostic value of symptom limited versus low level exercise stress test before discharge in patients with myocardial infarction treated with thrombolytics. | 0-164 | 0 | 164 | Prognostic value of @SUBJECT$ limited versus low level exercise stress test before discharge @PREDICAT$ @OBJECT$ with myocardial infarction treated with thrombolytics. |
Counterfact | preserve | 2128-2132 | 2128-2132 | T135 | with | PROCESS_OF | 2,128 | 2,132 | preserve | 2144-2151 | 2144-2151 | T126 | symptom | SignOrSymptom | 2,144 | 2,151 | preserve | 2119-2127 | 2119-2127 | T124 | patients | PatientOrDisabledGroup | 2,119 | 2,127 | A14 | Four of the 36 patients with a negative symptom limited test suffered cardiac events within a year (two patients had a myocardial infarction and two had bypass surgery). | 2097-2279 | 2,097 | 2,279 | Four of the 36 @OBJECT$ @PREDICAT$ a negative @SUBJECT$ limited test suffered cardiac events within a year (two patients had a myocardial infarction and two had bypass surgery). |
Fact | preserve | 137-144 | 137-144 | T11 | treated | TREATS | 137 | 144 | preserve | 150-163 | 150-163 | T8 | thrombolytics | PharmacologicSubstance | 150 | 163 | preserve | 115-136 | 126-136 | T7 | myocardial infarction | DiseaseOrSyndrome | 115 | 136 | A15 | Prognostic value of symptom limited versus low level exercise stress test before discharge in patients with myocardial infarction treated with thrombolytics. | 0-164 | 0 | 164 | Prognostic value of symptom limited versus low level exercise stress test before discharge in patients with @OBJECT$ @PREDICAT$ with @SUBJECT$ . |
Fact | preserve | 1643-1646 | 1643-1646 | T92 | had | PROCESS_OF | 1,643 | 1,646 | preserve | 1649-1670 | 1660-1670 | T91 | myocardial infarction | DiseaseOrSyndrome | 1,649 | 1,670 | preserve | 1626-1634 | 1626-1634 | T90 | patients | PatientOrDisabledGroup | 1,626 | 1,634 | A16 | During a follow up period of one year, six of the 75 patients died or had a myocardial infarction. | 1566-1671 | 1,566 | 1,671 | During a follow up period of one year, six of the 75 @OBJECT$ died or @PREDICAT$ a @SUBJECT$ . |
Counterfact | preserve | 1035-1042 | 1035-1042 | T69 | perform | ADMINISTERED_TO | 1,035 | 1,042 | preserve | 1052-1065 | 1061-1065 | T55 | exercise test | DiagnosticProcedure | 1,052 | 1,065 | preserve | 1012-1020 | 1012-1020 | T52 | patients | PatientOrDisabledGroup | 1,012 | 1,020 | A17 | Of the remaining 23 patients who could not perform an early exercise test (because of unstable angina, heart failure, or thrombus detected at echocardiography), five died or had a myocardial infarction and six underwent bypass surgery or percutaneous transluminal coronary angioplasty (PTCA) during a follow up period of one year. | 986-1340 | 986 | 1,340 | Of the remaining 23 @OBJECT$ who could not @PREDICAT$ an early @SUBJECT$ (because of unstable angina, heart failure, or thrombus detected at echocardiography), five died or had a myocardial infarction and six underwent bypass surgery or percutaneous transluminal coronary angioplasty (PTCA) during a follow up period of one year. |
Fact | preserve | 2418-2422 | 2418-2422 | T149 | with | PROCESS_OF | 2,418 | 2,422 | preserve | 2463-2473 | 2469-2473 | T145 | chest pain | SignOrSymptom | 2,463 | 2,473 | preserve | 2409-2417 | 2409-2417 | T142 | patients | PatientOrDisabledGroup | 2,409 | 2,417 | A18 | CONCLUSION: Symptom limited exercise testing soon after thrombolytically treated myocardial infarction will identify more patients with exercise induced ST depression or chest pain than a low level test, and seems safe. | 2280-2512 | 2,280 | 2,512 | CONCLUSION: Symptom limited exercise testing soon after thrombolytically treated myocardial infarction will identify more @OBJECT$ @PREDICAT$ exercise induced ST depression or @SUBJECT$ than a low level test, and seems safe. |
Fact | preserve | 2223-2226 | 2223-2226 | T137 | had | PROCESS_OF | 2,223 | 2,226 | preserve | 2229-2250 | 2240-2250 | T132 | myocardial infarction | DiseaseOrSyndrome | 2,229 | 2,250 | preserve | 2214-2222 | 2214-2222 | T131 | patients | PatientOrDisabledGroup | 2,214 | 2,222 | A19 | Four of the 36 patients with a negative symptom limited test suffered cardiac events within a year (two patients had a myocardial infarction and two had bypass surgery). | 2097-2279 | 2,097 | 2,279 | Four of the 36 patients with a negative symptom limited test suffered cardiac events within a year (two @OBJECT$ @PREDICAT$ a @SUBJECT$ and two had bypass surgery). |
Fact | preserve | 937-943 | 937-943 | T81 | caused | CAUSES | 937 | 943 | preserve | 954-962 | 954-962 | T67 | symptoms | SignOrSymptom | 954 | 962 | preserve | 921-936 | 927-936 | T65 | early awakening | SignOrSymptom | 921 | 936 | A1 | During a run-in period, patients had to show at least one nocturnal or early awakening caused by asthma symptoms that required rescue medication, and a >/= 15% overnight decrease in peak expiratory flow (PEF) on 3 of the preceding 7 d, in order to be randomized into this double-blind, double dummy, multicenter parallel group study (2-wk run-in period and 6 wk of treatment). | 844-1250 | 844 | 1,250 | During a run-in period, patients had to show at least one nocturnal or @OBJECT$ @PREDICAT$ by asthma @SUBJECT$ that required rescue medication, and a >/= 15% overnight decrease in peak expiratory flow (PEF) on 3 of the preceding 7 d, in order to be randomized into this double-blind, double dummy, multicenter parallel group study (2-wk run-in period and 6 wk of treatment). |
Fact | preserve | 439-441 | 439-441 | T48 | in | TREATS | 439 | 441 | preserve | 394-404 | 394-404 | T32 | salmeterol | OrganicChemical | 394 | 404 | preserve | 446-455 | 446-455 | T35 | asthmatic | DiseaseOrSyndrome | 446 | 455 | A2 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. | 289-686 | 289 | 686 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled @SUBJECT$ at 50 microgram taken twice daily @PREDICAT$ 126 @OBJECT$ patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. |
Fact | preserve | 439-441 | 439-441 | T48 | in | TREATS | 439 | 441 | preserve | 312-322 | 312-322 | T27 | bambuterol | OrganicChemical | 312 | 322 | preserve | 446-455 | 446-455 | T35 | asthmatic | DiseaseOrSyndrome | 446 | 455 | A3 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. | 289-686 | 289 | 686 | We compared oral @SUBJECT$ in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily @PREDICAT$ 126 @OBJECT$ patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. |
Fact | preserve | 0-10 | 0-10 | T10 | Comparison | compared_with | 0 | 10 | preserve | 19-29 | 19-29 | T2 | bambuterol | OrganicChemical | 19 | 29 | preserve | 42-52 | 42-52 | T4 | salmeterol | OrganicChemical | 42 | 52 | A4 | Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. | 0-129 | 0 | 129 | @PREDICAT$ of oral @SUBJECT$ and inhaled @OBJECT$ in patients with symptomatic asthma and using inhaled corticosteroids. |
Fact | preserve | 298-306 | 298-306 | T46 | compared | compared_with | 298 | 306 | preserve | 312-322 | 312-322 | T27 | bambuterol | OrganicChemical | 312 | 322 | preserve | 394-404 | 394-404 | T32 | salmeterol | OrganicChemical | 394 | 404 | A6 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. | 289-686 | 289 | 686 | We @PREDICAT$ oral @SUBJECT$ in a dose of 20 mg taken once daily in the evening with inhaled @OBJECT$ at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. |
Fact | preserve | 446-464 | 456-464 | T47 | asthmatic patients | PROCESS_OF | 446 | 464 | preserve | 446-455 | 446-455 | T35 | asthmatic | DiseaseOrSyndrome | 446 | 455 | preserve | 456-464 | 456-464 | T36 | patients | PatientOrDisabledGroup | 456 | 464 | A8 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. | 289-686 | 289 | 686 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 @SUBJECT$ @PREDICAT$ @OBJECT$ (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. |
Fact | preserve | 439-441 | 439-441 | T48 | in | TREATS | 439 | 441 | preserve | 312-322 | 312-322 | T27 | bambuterol | OrganicChemical | 312 | 322 | preserve | 456-464 | 456-464 | T36 | patients | PatientOrDisabledGroup | 456 | 464 | A9 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. | 289-686 | 289 | 686 | We compared oral @SUBJECT$ in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily @PREDICAT$ 126 asthmatic @OBJECT$ (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. |
Fact | preserve | 65-69 | 65-69 | T13 | with | PROCESS_OF | 65 | 69 | preserve | 88-94 | 88-94 | T7 | asthma | DiseaseOrSyndrome | 88 | 94 | preserve | 56-64 | 56-64 | T5 | patients | PatientOrDisabledGroup | 56 | 64 | A10 | Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. | 0-129 | 0 | 129 | Comparison of oral bambuterol and inhaled salmeterol in @OBJECT$ @PREDICAT$ symptomatic @SUBJECT$ and using inhaled corticosteroids. |
Fact | preserve | 53-55 | 53-55 | T11 | in | TREATS | 53 | 55 | preserve | 19-29 | 19-29 | T2 | bambuterol | OrganicChemical | 19 | 29 | preserve | 56-64 | 56-64 | T5 | patients | PatientOrDisabledGroup | 56 | 64 | A11 | Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. | 0-129 | 0 | 129 | Comparison of oral @SUBJECT$ and inhaled salmeterol @PREDICAT$ @OBJECT$ with symptomatic asthma and using inhaled corticosteroids. |
Fact | preserve | 2001-2004 | 2001-2004 | T137 | for | TREATS | 2,001 | 2,004 | preserve | 1990-2000 | 1990-2000 | T133 | salmeterol | OrganicChemical | 1,990 | 2,000 | preserve | 2024-2030 | 2024-2030 | T136 | asthma | DiseaseOrSyndrome | 2,024 | 2,030 | A12 | Once-daily oral bambuterol is a convenient, effective, and less expensive alternative to twice-daily inhaled salmeterol for treating nocturnal asthma. | 1869-2031 | 1,869 | 2,031 | Once-daily oral bambuterol is a convenient, effective, and less expensive alternative to twice-daily inhaled @SUBJECT$ @PREDICAT$ treating nocturnal @OBJECT$ . |
Fact | preserve | 215-224 | 215-224 | T25 | treatment | TREATS | 215 | 224 | preserve | 130-140 | 130-140 | T16 | Salmeterol | OrganicChemical | 130 | 140 | preserve | 228-234 | 228-234 | T22 | asthma | DiseaseOrSyndrome | 228 | 234 | A13 | Salmeterol inhaled twice-daily is now being used more frequently as additional treatment in asthma insufficiently controlled by inhaled corticosteroids. | 130-288 | 130 | 288 | @SUBJECT$ inhaled twice-daily is now being used more frequently as additional @PREDICAT$ in @OBJECT$ insufficiently controlled by inhaled corticosteroids. |
Fact | preserve | 53-55 | 53-55 | T11 | in | TREATS | 53 | 55 | preserve | 19-29 | 19-29 | T2 | bambuterol | OrganicChemical | 19 | 29 | preserve | 88-94 | 88-94 | T7 | asthma | DiseaseOrSyndrome | 88 | 94 | A14 | Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. | 0-129 | 0 | 129 | Comparison of oral @SUBJECT$ and inhaled salmeterol @PREDICAT$ patients with symptomatic @OBJECT$ and using inhaled corticosteroids. |
Fact | preserve | 439-441 | 439-441 | T48 | in | TREATS | 439 | 441 | preserve | 394-404 | 394-404 | T32 | salmeterol | OrganicChemical | 394 | 404 | preserve | 456-464 | 456-464 | T36 | patients | PatientOrDisabledGroup | 456 | 464 | A15 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled salmeterol at 50 microgram taken twice daily in 126 asthmatic patients (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. | 289-686 | 289 | 686 | We compared oral bambuterol in a dose of 20 mg taken once daily in the evening with inhaled @SUBJECT$ at 50 microgram taken twice daily @PREDICAT$ 126 asthmatic @OBJECT$ (60 bambuterol, 66 salmeterol) aged 18 to 74 yr who were treated for at least 4 wk with inhaled corticosteroids at a constant dose of 400 to 2,000 microgram/d or with oral corticosteroids at </= 20 mg/d. |
Fact | preserve | 53-55 | 53-55 | T11 | in | TREATS | 53 | 55 | preserve | 42-52 | 42-52 | T4 | salmeterol | OrganicChemical | 42 | 52 | preserve | 56-64 | 56-64 | T5 | patients | PatientOrDisabledGroup | 56 | 64 | A16 | Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. | 0-129 | 0 | 129 | Comparison of oral bambuterol and inhaled @SUBJECT$ @PREDICAT$ @OBJECT$ with symptomatic asthma and using inhaled corticosteroids. |
Fact | preserve | 53-55 | 53-55 | T11 | in | TREATS | 53 | 55 | preserve | 42-52 | 42-52 | T4 | salmeterol | OrganicChemical | 42 | 52 | preserve | 88-94 | 88-94 | T7 | asthma | DiseaseOrSyndrome | 88 | 94 | A17 | Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. | 0-129 | 0 | 129 | Comparison of oral bambuterol and inhaled @SUBJECT$ @PREDICAT$ patients with symptomatic @OBJECT$ and using inhaled corticosteroids. |
Fact | preserve | 422-431 | 422-431 | T42 | treatment | TREATS | 422 | 431 | preserve | 364-384 | 375-384 | T34 | salmeterol xinafoate | OrganicChemical | 364 | 384 | preserve | 446-452 | 446-452 | T39 | asthma | DiseaseOrSyndrome | 446 | 452 | A1 | OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma. | 278-453 | 278 | 453 | OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled @SUBJECT$ versus oral zafirlukast in the @PREDICAT$ of persistent @OBJECT$ . |
Fact | preserve | 385-391 | 385-391 | T41 | versus | compared_with | 385 | 391 | preserve | 364-384 | 375-384 | T34 | salmeterol xinafoate | OrganicChemical | 364 | 384 | preserve | 397-408 | 397-408 | T36 | zafirlukast | OrganicChemical | 397 | 408 | A3 | OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma. | 278-453 | 278 | 453 | OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled @SUBJECT$ @PREDICAT$ oral @OBJECT$ in the treatment of persistent asthma. |
Fact | preserve | 1306-1326 | 1317-1326 | T120 | Salmeterol treatment | compared_with | 1,306 | 1,326 | preserve | 1306-1316 | 1306-1316 | T99 | Salmeterol | OrganicChemical | 1,306 | 1,316 | preserve | 1414-1425 | 1414-1425 | T103 | zafirlukast | OrganicChemical | 1,414 | 1,425 | A4 | Salmeterol treatment resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P </= .001). | 1306-1692 | 1,306 | 1,692 | @SUBJECT$ @PREDICAT$ resulted in significantly greater improvements from baseline compared with @OBJECT$ for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P </= .001). |
Fact | preserve | 1870-1875 | 1870-1875 | T145 | using | ADMINISTERED_TO | 1,870 | 1,875 | preserve | 1884-1899 | 1884-1899 | T130 | corticosteroids | Hormone | 1,884 | 1,899 | preserve | 1800-1808 | 1800-1808 | T125 | patients | PatientOrDisabledGroup | 1,800 | 1,808 | A6 | CONCLUSION: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. | 1785-2071 | 1,785 | 2,071 | CONCLUSION: In @OBJECT$ with persistent asthma, most of whom were concurrently @PREDICAT$ inhaled @SUBJECT$ , treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. |
Fact | preserve | 244-246 | 244-246 | T27 | in | PROCESS_OF | 244 | 246 | preserve | 231-237 | 231-237 | T21 | asthma | DiseaseOrSyndrome | 231 | 237 | preserve | 247-257 | 247-257 | T22 | adolescent | AgeGroup | 247 | 257 | A7 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. | 79-277 | 79 | 277 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of @SUBJECT$ @PREDICAT$ @OBJECT$ and adult patients. |
Fact | preserve | 66-70 | 66-70 | T10 | with | PROCESS_OF | 66 | 70 | preserve | 71-77 | 71-77 | T6 | asthma | DiseaseOrSyndrome | 71 | 77 | preserve | 57-65 | 57-65 | T5 | patients | PatientOrDisabledGroup | 57 | 65 | A9 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. | 0-78 | 0 | 78 | Comparison of inhaled salmeterol and oral zafirlukast in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 137-189 | 179-189 | T29 | zafirlukast, a leukotriene receptor antagonist | TREATS | 137 | 189 | preserve | 137-148 | 137-148 | T18 | zafirlukast | OrganicChemical | 137 | 148 | preserve | 231-237 | 231-237 | T21 | asthma | DiseaseOrSyndrome | 231 | 237 | A10 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. | 79-277 | 79 | 277 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and @SUBJECT$ @PREDICAT$ , are both indicated for the treatment of @OBJECT$ in adolescent and adult patients. |
Fact | preserve | 137-189 | 179-189 | T25 | zafirlukast, a leukotriene receptor antagonist | ISA | 137 | 189 | preserve | 137-148 | 137-148 | T18 | zafirlukast | OrganicChemical | 137 | 148 | preserve | 158-189 | 179-189 | T19 | leukotriene receptor antagonist | OrganicChemical | 158 | 189 | A12 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. | 79-277 | 79 | 277 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and @SUBJECT$ @PREDICAT$ @OBJECT$ , are both indicated for the treatment of asthma in adolescent and adult patients. |
Fact | preserve | 54-56 | 54-56 | T8 | in | TREATS | 54 | 56 | preserve | 22-32 | 22-32 | T2 | salmeterol | OrganicChemical | 22 | 32 | preserve | 71-77 | 71-77 | T6 | asthma | DiseaseOrSyndrome | 71 | 77 | A13 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. | 0-78 | 0 | 78 | Comparison of inhaled @SUBJECT$ and oral zafirlukast @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 54-56 | 54-56 | T8 | in | TREATS | 54 | 56 | preserve | 42-53 | 42-53 | T4 | zafirlukast | OrganicChemical | 42 | 53 | preserve | 57-65 | 57-65 | T5 | patients | PatientOrDisabledGroup | 57 | 65 | A14 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. | 0-78 | 0 | 78 | Comparison of inhaled salmeterol and oral @SUBJECT$ @PREDICAT$ @OBJECT$ with asthma. |
Fact | preserve | 1809-1813 | 1809-1813 | T144 | with | PROCESS_OF | 1,809 | 1,813 | preserve | 1825-1831 | 1825-1831 | T127 | asthma | DiseaseOrSyndrome | 1,825 | 1,831 | preserve | 1800-1808 | 1800-1808 | T125 | patients | PatientOrDisabledGroup | 1,800 | 1,808 | A15 | CONCLUSION: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. | 1785-2071 | 1,785 | 2,071 | CONCLUSION: In @OBJECT$ @PREDICAT$ persistent @SUBJECT$ , most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. |
Fact | preserve | 1306-1326 | 1317-1326 | T119 | Salmeterol treatment | USES | 1,306 | 1,326 | preserve | 1317-1326 | 1317-1326 | T100 | treatment | TherapeuticOrPreventiveProcedure | 1,317 | 1,326 | preserve | 1306-1316 | 1306-1316 | T99 | Salmeterol | OrganicChemical | 1,306 | 1,316 | A16 | Salmeterol treatment resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P </= .001). | 1306-1692 | 1,306 | 1,692 | @OBJECT$ @PREDICAT$ @SUBJECT$ resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P </= .001). |
Fact | preserve | 0-10 | 0-10 | T7 | Comparison | compared_with | 0 | 10 | preserve | 22-32 | 22-32 | T2 | salmeterol | OrganicChemical | 22 | 32 | preserve | 42-53 | 42-53 | T4 | zafirlukast | OrganicChemical | 42 | 53 | A18 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. | 0-78 | 0 | 78 | @PREDICAT$ of inhaled @SUBJECT$ and oral @OBJECT$ in patients with asthma. |
Fact | preserve | 422-431 | 422-431 | T42 | treatment | TREATS | 422 | 431 | preserve | 397-408 | 397-408 | T36 | zafirlukast | OrganicChemical | 397 | 408 | preserve | 446-452 | 446-452 | T39 | asthma | DiseaseOrSyndrome | 446 | 452 | A19 | OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma. | 278-453 | 278 | 453 | OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral @SUBJECT$ in the @PREDICAT$ of persistent @OBJECT$ . |
Fact | preserve | 54-56 | 54-56 | T8 | in | TREATS | 54 | 56 | preserve | 22-32 | 22-32 | T2 | salmeterol | OrganicChemical | 22 | 32 | preserve | 57-65 | 57-65 | T5 | patients | PatientOrDisabledGroup | 57 | 65 | A20 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. | 0-78 | 0 | 78 | Comparison of inhaled @SUBJECT$ and oral zafirlukast @PREDICAT$ @OBJECT$ with asthma. |
Fact | preserve | 1911-1915 | 1911-1915 | T146 | with | USES | 1,911 | 1,915 | preserve | 1901-1910 | 1901-1910 | T131 | treatment | TherapeuticOrPreventiveProcedure | 1,901 | 1,910 | preserve | 1930-1940 | 1930-1940 | T133 | salmeterol | OrganicChemical | 1,930 | 1,940 | A21 | CONCLUSION: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. | 1785-2071 | 1,785 | 2,071 | CONCLUSION: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, @SUBJECT$ @PREDICAT$ inhaled @OBJECT$ provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. |
Fact | preserve | 2030-2037 | 2030-2037 | T147 | control | TREATS | 2,030 | 2,037 | preserve | 1994-2005 | 1994-2005 | T136 | zafirlukast | OrganicChemical | 1,994 | 2,005 | preserve | 2023-2029 | 2023-2029 | T138 | asthma | DiseaseOrSyndrome | 2,023 | 2,029 | A22 | CONCLUSION: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period. | 1785-2071 | 1,785 | 2,071 | CONCLUSION: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral @SUBJECT$ in overall @OBJECT$ @PREDICAT$ over the 4-week treatment period. |
Fact | preserve | 244-246 | 244-246 | T27 | in | PROCESS_OF | 244 | 246 | preserve | 231-237 | 231-237 | T21 | asthma | DiseaseOrSyndrome | 231 | 237 | preserve | 268-276 | 268-276 | T24 | patients | PatientOrDisabledGroup | 268 | 276 | A23 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. | 79-277 | 79 | 277 | BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of @SUBJECT$ @PREDICAT$ adolescent and adult @OBJECT$ . |
Fact | preserve | 54-56 | 54-56 | T8 | in | TREATS | 54 | 56 | preserve | 42-53 | 42-53 | T4 | zafirlukast | OrganicChemical | 42 | 53 | preserve | 71-77 | 71-77 | T6 | asthma | DiseaseOrSyndrome | 71 | 77 | A24 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. | 0-78 | 0 | 78 | Comparison of inhaled salmeterol and oral @SUBJECT$ @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1306-1326 | 1317-1326 | T118 | Salmeterol treatment | ISA | 1,306 | 1,326 | preserve | 1306-1316 | 1306-1316 | T99 | Salmeterol | OrganicChemical | 1,306 | 1,316 | preserve | 1317-1326 | 1317-1326 | T100 | treatment | TherapeuticOrPreventiveProcedure | 1,317 | 1,326 | A25 | Salmeterol treatment resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P </= .001). | 1306-1692 | 1,306 | 1,692 | @SUBJECT$ @PREDICAT$ @OBJECT$ resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P </= .001). |
Fact | preserve | 626-648 | 641-648 | T67 | corticosteroid regimen | USES | 626 | 648 | preserve | 641-648 | 641-648 | T55 | regimen | ResearchActivity | 641 | 648 | preserve | 626-640 | 626-640 | T54 | corticosteroid | Hormone | 626 | 640 | A26 | Patients, over 80% of whom were on a concurrent inhaled corticosteroid regimen, were treated for 4 weeks with either inhaled salmeterol xinafoate 42 microgram twice daily administered by means of a metered-dose inhaler or oral zafirlukast 20 mg twice daily. | 564-845 | 564 | 845 | Patients, over 80% of whom were on a concurrent inhaled @OBJECT$ @PREDICAT$ @SUBJECT$ , were treated for 4 weeks with either inhaled salmeterol xinafoate 42 microgram twice daily administered by means of a metered-dose inhaler or oral zafirlukast 20 mg twice daily. |
Fact | preserve | 1047-1049 | 1047-1049 | T52 | in | PROCESS_OF | 1,047 | 1,049 | preserve | 1029-1036 | 1029-1036 | T49 | obesity | DiseaseOrSyndrome | 1,029 | 1,036 | preserve | 1050-1053 | 1050-1053 | T50 | men | PopulationGroup | 1,050 | 1,053 | A3 | RESULTS: Prevalence of obesity was 12.1% in men and 18.4% in women. | 1006-1073 | 1,006 | 1,073 | RESULTS: Prevalence of @SUBJECT$ was 12.1% @PREDICAT$ @OBJECT$ and 18.4% in women. |
Fact | preserve | 183-193 | 183-193 | T10 | prevalence | OCCURS_IN | 183 | 193 | preserve | 197-204 | 197-204 | T7 | obesity | DiseaseOrSyndrome | 197 | 204 | preserve | 220-244 | 234-244 | T9 | general population | PopulationGroup | 220 | 244 | A4 | OBJECTIVE: To examine associations between sociodemographic, dietary factors and physical activity and the prevalence of obesity in the Belgian general population. | 69-245 | 69 | 245 | OBJECTIVE: To examine associations between sociodemographic, dietary factors and physical activity and the @PREDICAT$ of @SUBJECT$ in the Belgian @OBJECT$ . |
Fact | preserve | 1137-1139 | 1137-1139 | T57 | in | PROCESS_OF | 1,137 | 1,139 | preserve | 1109-1116 | 1109-1116 | T53 | obesity | DiseaseOrSyndrome | 1,109 | 1,116 | preserve | 1153-1165 | 1157-1165 | T55 | age category | AgeGroup | 1,153 | 1,165 | A5 | In both sexes, prevalence of obesity increased gradually in each 10-year age category (P<0.0001) and steeply decreased with level of education. | 1074-1229 | 1,074 | 1,229 | In both sexes, prevalence of @SUBJECT$ increased gradually @PREDICAT$ each 10-year @OBJECT$ (P<0.0001) and steeply decreased with level of education. |
Possible | preserve | 1910-1913 | 1910-1913 | T97 | for | TREATS | 1,910 | 1,913 | preserve | 1880-1895 | 1880-1895 | T92 | antidepressants | PharmacologicSubstance | 1,880 | 1,895 | preserve | 1935-1951 | 1941-1951 | T94 | major depression | MentalOrBehavioralDysfunction | 1,935 | 1,951 | A1 | Adjunctive antidepressants may be useful for patients with major depression who are not acutely ill. | 1869-1976 | 1,869 | 1,976 | Adjunctive @SUBJECT$ may be useful @PREDICAT$ patients with @OBJECT$ who are not acutely ill. |
Possible | preserve | 1910-1913 | 1910-1913 | T97 | for | TREATS | 1,910 | 1,913 | preserve | 1880-1895 | 1880-1895 | T92 | antidepressants | PharmacologicSubstance | 1,880 | 1,895 | preserve | 1914-1922 | 1914-1922 | T93 | patients | PatientOrDisabledGroup | 1,914 | 1,922 | A2 | Adjunctive antidepressants may be useful for patients with major depression who are not acutely ill. | 1869-1976 | 1,869 | 1,976 | Adjunctive @SUBJECT$ may be useful @PREDICAT$ @OBJECT$ with major depression who are not acutely ill. |
Fact | preserve | 1639-1641 | 1639-1641 | T81 | in | PROCESS_OF | 1,639 | 1,641 | preserve | 1624-1638 | 1630-1638 | T77 | manic symptoms | MentalOrBehavioralDysfunction | 1,624 | 1,638 | preserve | 1642-1650 | 1642-1650 | T78 | patients | PatientOrDisabledGroup | 1,642 | 1,650 | A3 | There was little evidence to support adjunctive lithium for depressive symptoms and no evidence concerning its use for manic symptoms in patients with schizophrenia. | 1493-1670 | 1,493 | 1,670 | There was little evidence to support adjunctive lithium for depressive symptoms and no evidence concerning its use for @SUBJECT$ @PREDICAT$ @OBJECT$ with schizophrenia. |
Fact | preserve | 1651-1655 | 1651-1655 | T82 | with | PROCESS_OF | 1,651 | 1,655 | preserve | 1656-1669 | 1656-1669 | T79 | schizophrenia | MentalOrBehavioralDysfunction | 1,656 | 1,669 | preserve | 1642-1650 | 1642-1650 | T78 | patients | PatientOrDisabledGroup | 1,642 | 1,650 | A4 | There was little evidence to support adjunctive lithium for depressive symptoms and no evidence concerning its use for manic symptoms in patients with schizophrenia. | 1493-1670 | 1,493 | 1,670 | There was little evidence to support adjunctive lithium for depressive symptoms and no evidence concerning its use for manic symptoms in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Probable | preserve | 1745-1752 | 1745-1752 | T89 | treated | TREATS | 1,745 | 1,752 | preserve | 1806-1829 | 1815-1829 | T87 | atypical antipsychotics | PharmacologicSubstance | 1,806 | 1,829 | preserve | 1727-1735 | 1727-1735 | T84 | patients | PatientOrDisabledGroup | 1,727 | 1,735 | A5 | CONCLUSIONS: Empirical data suggest that both groups of patients are best treated by optimizing antipsychotic treatment and that atypical antipsychotics may prove to be most effective. | 1671-1868 | 1,671 | 1,868 | CONCLUSIONS: Empirical data suggest that both groups of @OBJECT$ are best @PREDICAT$ by optimizing antipsychotic treatment and that @SUBJECT$ may prove to be most effective. |
Fact | preserve | 1262-1286 | 1277-1286 | T70 | antidepressant treatment | USES | 1,262 | 1,286 | preserve | 1277-1286 | 1277-1286 | T62 | treatment | TherapeuticOrPreventiveProcedure | 1,277 | 1,286 | preserve | 1262-1276 | 1262-1276 | T61 | antidepressant | PharmacologicSubstance | 1,262 | 1,276 | A6 | There was evidence supporting adjunctive antidepressant treatment for schizophrenic and schizoaffective patients who develop a major depressive syndrome after remission of acute psychosis, but there were mixed results for treatment of subsyndromal depression. | 1215-1492 | 1,215 | 1,492 | There was evidence supporting adjunctive @OBJECT$ @PREDICAT$ @SUBJECT$ for schizophrenic and schizoaffective patients who develop a major depressive syndrome after remission of acute psychosis, but there were mixed results for treatment of subsyndromal depression. |